Corvus Pharmaceuticals (CRVS)
(Delayed Data from NSDQ)
$1.45 USD
-0.03 (-2.03%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.44 -0.01 (-0.69%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth D Momentum C VGM
Income Statements
Fiscal Year end for Corvus Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 23 | 33 | 39 | 44 | 49 |
Income After Depreciation & Amortization | -23 | -33 | -39 | -44 | -49 |
Non-Operating Income | -4 | -9 | -5 | 38 | 2 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -27 | -41 | -43 | -6 | -47 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -27 | -41 | -43 | -6 | -47 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -27 | -41 | -43 | -6 | -47 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -24 | -32 | -38 | -43 | -49 |
Depreciation & Amortization (Cash Flow) | -1 | 0 | 1 | 1 | 0 |
Income After Depreciation & Amortization | -23 | -33 | -39 | -44 | -49 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 48.03 | 46.55 | 41.85 | 29.48 | 29.35 |
Diluted EPS Before Non-Recurring Items | -0.56 | -0.89 | -1.03 | -1.47 | -1.59 |
Diluted Net EPS (GAAP) | -0.56 | -0.89 | -1.03 | -0.20 | -1.59 |
Fiscal Year end for Corvus Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 5.65 | 5.57 | 5.62 | 6.57 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -5.65 | -5.57 | -5.62 | -6.57 |
Non-Operating Income | NA | -1.00 | -0.44 | -0.88 | -1.30 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -6.65 | -6.00 | -6.50 | -7.87 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -6.65 | -6.00 | -6.50 | -7.87 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -6.65 | -6.00 | -6.50 | -7.87 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 49.04 | 48.97 | 47.50 | 46.56 |
Diluted EPS Before Non-Recurring Items | NA | -0.14 | -0.12 | -0.14 | -0.17 |
Diluted Net EPS (GAAP) | NA | -0.13 | -0.12 | -0.14 | -0.17 |